Search research articles
Contact Us
Filters
Showing results (11-20 of 102) with videos related to
Page
of 11
Sort By:
Molecular Cancer Therapeutics
|
December 19, 2006
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Warren Fiskus, Michael Pranpat, Maria Balasis, et al.
Neuro-Oncology
|
May 1, 2008
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
Chunrong Yu, Bret B Friday, Lin Yang, et al.
Clinical Epigenetics
|
November 19, 2020
Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
Jessica M Salmon, Michael Bots, Eva Vidacs, et al.
Molecular Cancer Therapeutics
|
October 15, 2008
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Roberto R Rosato, Jorge A Almenara, Sonia C Maggio, et al.
Clinical Epigenetics
|
January 29, 2015
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
Jessica M Salmon, Michael Bots, Eva Vidacs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
Chunrong Yu, Bret B Friday, Jin-Ping Lai, et al.
Plos One
|
August 24, 2012
ING1 and 5-azacytidine act synergistically to block breast cancer cell growth
Satbir Thakur, Xiaolan Feng, Zhong Qiao Shi, et al.
Cancer Research
|
September 18, 2004
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
David Z Qian, Xiaofei Wang, Sushant K Kachhap, et al.
Molecular Cancer Therapeutics
|
September 20, 2005
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Liwei Chen, Songshu Meng, Hai Wang, et al.
Molecular Cancer Therapeutics
|
November 9, 2005
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Roberto R Rosato, Jorge A Almenara, Sonia C Maggio, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 102) with videos related to
Sort By:
Page
of 11
Molecular Cancer Therapeutics
|
December 19, 2006
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Warren Fiskus, Michael Pranpat, Maria Balasis, et al.
Neuro-Oncology
|
May 1, 2008
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
Chunrong Yu, Bret B Friday, Lin Yang, et al.
Clinical Epigenetics
|
November 19, 2020
Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
Jessica M Salmon, Michael Bots, Eva Vidacs, et al.
Molecular Cancer Therapeutics
|
October 15, 2008
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Roberto R Rosato, Jorge A Almenara, Sonia C Maggio, et al.
Clinical Epigenetics
|
January 29, 2015
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
Jessica M Salmon, Michael Bots, Eva Vidacs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
Chunrong Yu, Bret B Friday, Jin-Ping Lai, et al.
Plos One
|
August 24, 2012
ING1 and 5-azacytidine act synergistically to block breast cancer cell growth
Satbir Thakur, Xiaolan Feng, Zhong Qiao Shi, et al.
Cancer Research
|
September 18, 2004
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
David Z Qian, Xiaofei Wang, Sushant K Kachhap, et al.
Molecular Cancer Therapeutics
|
September 20, 2005
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Liwei Chen, Songshu Meng, Hai Wang, et al.
Molecular Cancer Therapeutics
|
November 9, 2005
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Roberto R Rosato, Jorge A Almenara, Sonia C Maggio, et al.
Page
of 11